What the New VA and HHS Partnership Means for Psychedelic Therapy for Veterans

On July 13, 2026, the Department of Veterans Affairs and the Department of Health and Human Services signed a five-year partnership to accelerate research into psychedelic therapy for veterans. The agreement, reported by Military.com and signed by VA Secretary Doug Collins and HHS Secretary Robert F. Kennedy Jr., focuses on four compounds under study: psilocybin, MDMA, ketamine, and ibogaine. It could touch the lives of more than one million veterans living with serious mental illness.

This is a research partnership, not a treatment rollout. Nothing named here is FDA-approved for general care yet. What it signals is a shift: the country is beginning to study, with real rigor, what many in the plant medicine community have held as sacred for generations.

Why this moment matters

Nearly six million veterans live with mental illness or substance use challenges. About one million carry a serious mental illness diagnosis. These are people who answered a call, and who deserve care that meets the depth of what they carry.

The partnership sets out to do a few concrete things:

• Grow participation in clinical trials (the VA already runs 20 active trials with more than $23 million in outside funding)

• Train the clinicians and physicians who guide the therapy, not only treat individual patients

• Share research data with the FDA

• Build treatment protocols and educational materials

• Coordinate across federal agencies

As Secretary Kennedy put it: "Strong evidence, not ideology or politics, must guide our medical decision making." Secretary Collins pointed to what comes after the research: "It's not just the veteran getting treated; it's training the clinicians who actually perform the therapy."

What this does not mean yet

Care is not available through this program today. MDMA-assisted therapy alone may ask for more than 100 clinical hours per veteran, and the whole framework is built on a five-year horizon that depends on FDA approval. This is the beginning of a road, walked carefully.

Where Psychable fits

Psychable is the trust layer for this kind of care. Psychable holds the space before and after: a place to find vetted practitioners, including practitioners who work with PTSD, to learn about the modalities, and to prepare with intention. You can also explore vetted clinics in your area. When you or someone you love is ready to explore, we help you do it with clear eyes and sovereignty intact.

Frequently asked questions

What did the VA and HHS actually announce?
A five-year memorandum of understanding, signed July 13, 2026, to accelerate research into psychedelic-assisted therapy for veterans. It implements Executive Order 14401 on treatments for serious mental illness.

Which psychedelics are being studied?
Four are named in the partnership: psilocybin, MDMA, ketamine, and ibogaine.

Can a veteran get psychedelic therapy through the VA now?
Not yet. This is a research framework. Availability depends on FDA approval and the trials underway.

How many veterans could this help?
The partnership could affect more than one million veterans living with serious mental illness.

How do I explore options in the meantime?
You can browse practitioners and learn about the modalities on Psychable. Always consult a qualified medical professional before beginning any therapy.

This article is for educational purposes only and is not medical advice. Psychable is not a medical provider and does not offer or procure any controlled substance. Psychedelic compounds discussed here are under research and are not FDA-approved for general treatment. Always consult a qualified medical professional before pursuing any therapy.

Source

VA-HHS psychedelic therapy partnership, announced July 13, 2026.
Primary reference: https://www.military.com/va-hhs-launch-new-psychedelic-therapy-partnership-that-will-impact-more-than-1-million-veterans